Lehman David Aaron sold $32K of LUNG

Lehman David Aaron (General Counsel) sold 14,334 shares of Pulmonx Corp (LUNG) at $2.26 across 4 trades on 2026-09-01.

Original reporting
SEC EDGAR · Lehman David Aaron
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LUNG
Bearish
medium confidence
Mentioned
$LUNG
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGBearishLow
01

Why it matters

A modest insider sell may prompt short‑term caution but is unlikely to affect long‑term valuation.

02

Market read

Insider sale of $32K is a low‑impact event; traders may note but not act on it.

03

What to watch

Potential upcoming FDA filing or clinical data could offset any negative perception.

Relevance 3/10Novelty 4/10Timing: filed post‑market on 2026‑09‑03, reflects 2026‑09‑01 transaction

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$LUNGBearishMedium confidence
Context

General Counsel David Aaron sold 14,334 shares of Pulmonx Corp for $32,394, reducing his stake to 361,827 shares.

Expected impact

Potential short-term dip of 0.5‑1% as market digests the sale.

Evidence & confidence

Sale amount is small relative to market cap; insider is a senior officer, but no 10b5‑1 plan and no broader context.

Market effects

Minimal impact on the broader biotech/respiratory device sector.

No significant regional effect; Pulmonx trades primarily on US exchanges.

Limited global relevance beyond investors tracking insider activity.

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Pulmonx Corp

    Medical device company focused on lung disease treatments, ticker LUNG.

  • David Aaron Lehman

    General Counsel and officer at Pulmonx Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LUNGMed

Pulmonx Corporation: Pulmonx Announces Publication of CONVERT Trial Results for AeriSeal System

Pulmonx Corporation (Nasdaq: LUNG) announced the publication of CONVERT Trial results for its AeriSeal System, showing 75.8% of patients with severe emphysema and collateral ventilation had successful treatment. The study suggests the system could enable subsequent treatment with Zephyr Valves, improving lung function and quality of life. Pulmonx is now conducting the CONVERT II Pivotal Trial to support a U.S. FDA Premarket Approval application for the AeriSeal System.

$LUNGMed

Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.